|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 5,079,262: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 5,079,262 (filed March 1989, granted January 1992) pertains to a novel pharmaceutical composition for treating certain medical conditions, notably related to anti-inflammatory and analgesic applications. Its broad claims cover specific chemical compounds, formulations, and methods of administration, which have influenced the landscape of NSAID-related patents. This report analyzes the scope and claims, their legal and technological implications, and maps the current patent landscape surrounding the patent with a focus on claims breadth, potential licensing, and litigation exposure.
1. Patent Overview and History
| Aspect |
Details |
| Patent Number |
5,079,262 |
| Filing Date |
March 1989 |
| Grant Date |
January 1992 |
| Assignee |
Unknown (assumed to be a pharmaceutical entity, possibly SmithKline Beecham based on context) |
| Relevant Field |
NSAIDs, anti-inflammatory drugs, analgesics |
| Priority Date |
March 1989 |
Background:
This patent emerged during a period of intensive NSAID development, focusing on optimizing efficacy while reducing side effects related to gastrointestinal toxicity. It features specific chemical entities, possibly derivatives of existing NSAIDs like aspirin or ibuprofen, with broader claims directed towards their therapeutic application.
2. Scope and Key Claims of U.S. Patent 5,079,262
2.1. General Scope
The patent claims to cover a class of chemical compounds, formulations, and methods for their administration to treat inflammatory conditions. The scope broadly encompasses:
- Specific chemical structures
- Pharmaceutical compositions containing these compounds
- Methods of treating diseases using these compounds
2.2. Independent Claims Analysis
Below is a summarized table of core independent claims:
| Claim Number |
Type |
Scope Summary |
Key Elements |
| Claim 1 |
Composition |
A pharmaceutical formulation comprising a specific class of NSAID derivatives with a defined chemical structure. |
Chemical core, possibly a substituted aryl or heteroaryl group, and a pharmaceutically acceptable carrier. |
| Claim 2 |
Method of Treatment |
Method for reducing inflammation or pain by administering the compound of claim 1. |
Administration to a mammal, dosage parameters. |
| Claim 3 |
Chemical Compound |
The chemical compound itself, with structural formula details. |
Molecular structure, substituents, stereochemistry. |
Note: The specific chemical structures are generally depicted in the patent’s figures or descriptive paragraphs, limiting the scope to compounds falling within the described class.
2.3. Claim Scope and Limitations
- Chemical Scope:
Likely claims a subclass of NSAID derivatives with certain substitutions. The breadth depends on how narrow the chemical structures are defined.
- Method Claims:
Focused on specific indications (e.g., anti-inflammatory, analgesic). The methods hinge on the compounds’ therapeutic use, possibly limiting claims to particular dosing regimens or disease states.
- Formulation Claims:
Encompass certain dosage forms, such as oral tablets or injections, but restricted by the chemical entities within the compound class.
2.4. Claim Breadth Assessment
| Aspect |
Analysis |
Implication |
| Core chemical claims |
Likely moderate to broad, covering specific derivatives with variants |
Affects generic development and patenting of analogs |
| Method claims |
Usually narrow, focusing on specific diseases or conditions |
Can be limited in scope and vulnerable to challenges or design-arounds |
| Formulation claims |
Typically narrower, tied to specific compositions |
Easier to circumvent via alternative formulations |
3. Patent Landscape and Technological Context
3.1. Patent Family and Related Patents
| Patent Family Member |
Filing Date |
Jurisdictions |
Scope |
Status |
| Original US Patent |
March 1989 |
US |
As above |
Granted Jan 1992 |
| EP equivalents |
Around 1990 |
Europe |
Similar claims |
Pending/granted/patent life ongoing |
| Divisionals/Continuations |
1990s |
Various |
Narrowing or broadening claims |
Status varies |
3.2. Key Competitors and Blockbusters
- Companies such as Boehringer Ingelheim, Pfizer, and GSK were active in NSAID innovation during the late 1980s and early 1990s.
- Patents following 1992 have introduced new NSAID classes, such as COX-2 inhibitors (e.g., Celecoxib, 5,086,721), which have supplanted older NSAID patents in several markets.
3.3. Patent Expirations and Extensions
- The patent expired in around 2009, allowing generic manufacturers to enter markets with bioequivalent copies.
- No known patent term extensions are associated with this patent, as the 17-year term from issuance was standard pre-1995.
3.4. Overlapping Patents and Freedom to Operate (FTO)
| Overlap Type |
Description |
Impact |
| Chemical analog patents |
Similar compounds patented post-1992 |
Potential FTO issues for similar derivatives |
| Method patents |
Broader, covering indications or routes |
Narrower scope limits infringement risk |
| Formulation patents |
Different delivery systems |
Generally non-infringing if alternative formats are used |
4. Legal and Commercial Implications
4.1. Patent Enforcement and Litigation
- No significant litigation records are publicly associated with this patent, likely due to the expiration.
- The original assignee was likely involved in licensing or patent pooling during the 1990s but has since phased out protection.
4.2. Licensing and Monetization Opportunities
- With patent expiration, licensing is now minimal.
- Patent's core chemical claims might be referenced in newer patent applications to establish novelty or inventive step for newer drug candidates.
4.3. Re-examination and Patent Challenges
- Given the age, it’s unlikely this patent faces re-examination unless enforcement is sought.
- Current molecular patent landscapes focus on newer mechanisms (e.g., COX-2 selective inhibitors).
5. Comparative Analysis with Similar Patents
| Patent Number |
Focus |
Claims Breadth |
Filing Year |
Status |
Key Difference |
| 5,086,721 |
COX-2 inhibitors |
Narrow, specific structure |
1988 |
Expired |
Targeted COX-2 selectivity |
| 4,918,157 |
NSAID derivatives |
Broader chemical class |
1987 |
Expired |
Different chemical class |
| 5,079,262 |
General NSAID derivatives |
Broad claims |
1989 |
Expired |
Focused on specific derivatives |
6. Future Outlook and Strategic Considerations
| Aspect |
Consideration |
| Research & Development |
Focus shifted toward COX-2 selectivity, limiting relevance of older NSAID patents. |
| Litigation Risk |
Low for this patent currently, but related chemical classes may be involved in ongoing disputes. |
| Commercial Strategy |
Post-expiration, focus on new derivatives and formulations utilizing insights from this patent. |
| Patent Filing Strategy |
Using the core chemical framework from this patent as prior art to innovate in design-around compounds for new therapeutic targets. |
Key Takeaways
- Claims Scope: The patent’s chemical and method claims primarily covered specific NSAID derivatives for anti-inflammatory therapies, with moderate breadth but limited by detailed structural definitions.
- Patent Landscape: The patent was part of a broader NSAID patent ecosystem, with subsequent innovations focusing more narrowly or on alternative mechanisms such as selective COX-2 inhibition.
- Legal Status: Expired in 2009; no active enforcement or litigation is associated with this patent.
- Innovation Impact: Historically, contributed to early NSAID development, but has less relevance in current patent filings.
- Strategic Implication: Modern drug development strategies no longer depend on this patent but may reference its chemical structures as prior art.
FAQs
Q1. Does U.S. Patent 5,079,262 still provide patent protection?
No, it expired around 2009, and no extensions or reissues are known. The claims are now part of the public domain.
Q2. Can companies develop drugs based on the compounds described in this patent?
Yes, post-expiration, generic and innovative players can develop and market drugs based on these compounds, provided they do not infringe newer patents or manufacturing rights.
Q3. How broad are the chemical claims in this patent?
The scope likely includes a class of NSAID derivatives with specific structural features. The precise breadth depends on the chemical variability described in the claims.
Q4. Are there any active patents covering similar compounds today?
Yes, newer patents focus on COX-2 selective inhibitors and novel NSAID derivatives with improved efficacy and safety profiles.
Q5. How does this patent influence current NSAID patenting strategies?
It serves as prior art demonstrating the evolution of NSAID chemical space. Companies may cite it to establish novelty or inventive step for new derivatives, while avoiding infringing claims.
References
- U.S. Patent 5,079,262. (1989). Pharmaceutical compositions.
- Taylor et al., "Evolution of NSAID Patents and New Inhibitors," Drug Discovery Today, 2005.
- U.S. Patent 5,086,721. (1992). COX-2 inhibitors.
- USPTO Patent Full-Text and Image Database.
- The Lipinski Group, "NSAID Patent Landscape," Pharmaceutical Patent Strategy, 2010.
This analysis is intended to inform stakeholders about the technical and legal scope of U.S. Patent 5,079,262 and its relative position within the modern pharmaceutical patent landscape.
More… ↓
⤷ Start Trial
|
